Entities / Company
Illumina.
American company that develops systems for the analysis of genetic variation
- Reports this week
- 1
- Active events
- 1
- Connections
- 154
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Earlier this month
-
VOO index undergoes changes including adding Illumina and Bloom Energy, while Builders FirstSource is removed. Separately, Fisher Investments promotes VOO strategies.Some support2 reports
-
Illumina achieved S&P 500 inclusion via index rebalancing, with the company headquartered in San Diego, CA.Some support1 report
-
Illumina is accelerating the adoption of its technologies in clinical markets across Canada.Some support1 report
-
Several companies, including Everpure and Bloom Energy Corporation, are scheduled to be added to the S&P 500 index, replacing existing members.Some support2 reports
-
Illumina and MindWalk Holdings Corp. have partnered, with both companies operating in the field of AI-enabled drug discovery.Some support1 report
-
Meiji Yasuda Life Insurance Co increased its stake in Illumina shares and sold stock under a trading plan.Some support1 report
One to three months ago
-
TD Cowen raised its price objective on Illumina stock on August 26, 2026.Some support1 report
-
Several companies, including Guardant Health and Myriad Genetics, are competing in the liquid biopsy market.Some support1 report1 development inside
-
MedLife and Illumina developed a full workflow in Romania using the NovaSeq X Plus platform.Some support1 report
-
Illumina is offering its services in the US, UK, and Singapore, and providing analyst ratings.Some support1 report
-
Illumina and Bio-Rad Laboratories collaborate on advanced life science technologies.Some support1 report1 development inside
-
Illumina reported its financial results, showing a year-on-year revenue growth of 9.4% on August 4, 2026.Some support1 report
-
Citigroup issued a rating report on Illumina, while MarketBeat aggregated the stock rating data.Some support3 reports
-
Canaccord raised its price target for Illumina shares, noting that revenue growth driven by clinical customers and NovaSeq X adoption is key to expansion goals.Some support2 reports1 development inside
-
Illumina reported that its Q2 revenue and EPS surpassed market expectations on July 30, 2026.Some support1 report
-
Morgan Stanley grew its holdings in Illumina, and PNC Financial Services Group increased its holdings in Illumina shares on July 29, 2026.Some support1 report
-
NIH grant uncertainty is causing delays in academic projects involving various research entities.Some support1 report1 development inside
-
Fifth Third Bancorp increased its stake in Illumina stock on July 18, 2026.Some support1 report
-
Illumina faces challenges from China's entity list and potential upside from Trump-era tariffs.Some support1 report
-
Barclays raised its price target on Illumina, which appointed an Eli Lilly executive to its board, while Roche launched a cheaper gene sequencing machine.Some support2 reports
Gone quiet
No new reports in 90+ days-
Daiwa Securities Group upgraded its stock rating and price target for Illumina on June 29, 2026, while Royal Bank of Canada began coverage with an outperform rating.Some support4 reports
-
The acquisition of SomaLogic by Illumina is expanding Illumina's capabilities into proteomics and precision medicine.Speculative5 reports
-
Illumina and Eli Lilly are strategically aligning through corporate appointments, including appointing an executive from Eli Lilly to another company's board.Some support1 report
-
Illumina SVP sold 700 shares of the company.Some support1 report
-
Royal Bank of Canada initiated coverage on Illumina stock.Some support1 report
-
Morgan Stanley and Norges Bank boosted their holdings in Illumina during the 4th quarter.Some support1 report
-
Illumina faces regulatory uncertainties in China.Some support1 report
-
Illumina faces restricted instrument exports to China, prompting regulatory changes and analyst scrutiny from Bank of America.Speculative1 report
-
Illumina, AbbVie, Abbott Laboratories, Qiagen, and Eli Lilly are major players in the US personalized medicine market and are investing in related R&D.Some support1 report1 development inside
-
Emerging competition from Roche is a near-term concern for Illumina.Speculative1 report
-
Government support is fueling biotech innovation involving Illumina and Roche.Some support1 report
-
Market growth in personalized medicine is being driven by demand, involving major players like Roche and Illumina.Some support1 report
-
RingCentral, Hershey, and Illumina were analyzed for cash-producing stock risks on August 22, 2025.Some support2 reports
-
Illumina acquired SomaLogic for cash and royalties.Some support2 reports1 development inside
-
Standard BioTools acquired SomaLogic, retaining reagent rights for Illumina, following a strategic sale of SomaLogic to Illumina.Speculative1 report
-
Illumina appointed Jacob Thaysen as CEO and Director.Speculative1 report
-
Illumina announced an agreement to acquire SomaLogic on September 3, 2025, utilizing SomaLogic's technology for new assays.Some support2 reports2 developments inside
-
Grail was formed following a spin-off from Illumina, and Morgan Stanley reiterated its 'Equal Weight' stance on the companies.Speculative3 reports
-
Illumina was ranked second overall in the United States as of July 10, 2025.Some support1 report
-
Illumina announced its results from San Diego.Some support1 report
-
Illumina and Agenus were noted to operate within the same industry.Some support1 report
-
Illumina and Qiagen are noted as top players in the tumor profiling market experiencing growth in Europe.Some support1 report
-
Illumina and Harmony Biosciences Holdings, Inc. were classified as stocks in the Medical-Biomedical and Genetics sector on July 15, 2025.Some support1 report
-
Sea expanded its services across Southeast Asia, with profitability analyses involving Sprinklr and Illumina.Some support1 report
-
Illumina and DaVita HealthCare reported positive ESP figures on July 22, 2025.Some support1 report
-
Cathie Wood invested in Illumina's disruptive life sciences.Some support2 reports
-
Illumina sold genomic-sequencing systems with software vulnerabilities, leading to an FDA warning.Some support1 report
-
Baron Funds highlighted Illumina in its investor letter on August 5, 2025.Some support1 report
-
Illumina reported that Europe contributed 29.3% of its total revenue in August 2025.Some support1 report
-
Illumina, Pacific Biosciences, Microsoft, and Monster Beverage were mentioned as thematic investing winners in the life sciences tools and services segment.Some support2 reports
-
Illumina, Twist Bioscience, Ginkgo Bioworks, Amyris, Cargill, Moderna, and Vertex Pharmaceuticals are all key players in the AI in Synthetic Biology Market.Some support2 reports
-
GRAIL reported an impairment of assets related to its acquisition of Illumina.Some support2 reports
-
Illumina Inc. is based in San Diego, CA.Some support1 report
-
Rate cut speculation on August 14, 2025, benefited growth sectors, including healthcare companies like Clover Health, Surgery Partners, Illumina, and Bruker.Some support2 reports
-
Illumina is establishing its regional head in Singapore.Some support1 report
-
Illumina and Thermo Fisher Scientific are key players in the DNA forensics market.Some support1 report
-
MicroGenDX incorporated Illumina's MiSeq platform to deliver leading-edge NGS testing, quickly identifying C. acnes.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Illumina this week
News at the entities that move Illumina most-
Nasdaq StructuralApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Illumina
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Illumina
-
Fifth Third Bancorp TransactionalFifth Third Bancorp increased its stake in Crescent Energy Company on June 17, 2026.Moves Illumina
-
Morgan Stanley TransactionalFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Illumina
-
Donald Trump Shared contextThe Trump administration utilized the Department of Health & Human Services for an AI tool.Moves Illumina
-
GRAIL StructuralA lawsuit was filed against GRAIL in the Northern District of California.Moves Illumina
Connections
The 30 strongest of 154, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
SomaLogic Structural
Illumina acquired SomaLogic and integrated its technology into its multiomics and proteomics ecosystem.
-
GRAIL Structural
GRAIL maintains a structural financial relationship with Illumina as its largest shareholder and through ongoing royalty obligations.
-
Nasdaq Structural
Illumina is a publicly traded company whose shares are listed and traded on the Nasdaq exchange.
-
Jakob Wedel Transactional
Jakob Wedel, identified as an SVP, sold 700 shares of Illumina under a trading plan.
-
Fifth Third Bancorp Transactional
Fifth Third Bancorp increased its stake in Illumina stock.
-
FDA Structural
FDA provides regulatory approval necessary for Illumina's commercialization of CDx indications.
-
MedLife Structural
MedLife relies on Illumina's NovaSeq X Plus platform for its operations.
-
Morgan Stanley Transactional
Morgan Stanley increased its holdings in Illumina, resulting in a 66.0% boost during the fourth quarter.
Show all 30 connections
-
Eli Lilly and Company Structural
Illumina received an executive appointment from Eli Lilly and Company, establishing a formal governance link.
-
Singapore Structural
Illumina has established a regional head office and offers services within Singapore.
-
VOO Structural
VOO includes Illumina in its holdings, and Illumina's market performance influences the index VOO tracks.
-
Norges Bank Transactional
Norges Bank purchased a new stake in Illumina during the 4th quarter.
-
Europe Shared context
Illumina operates within the European market, which contributes significantly to its total revenue.
-
Hoffmann-La Roche Operational
Illumina and Hoffmann-La Roche are actively competing in the gene sequencing and liquid biopsy markets.
-
Leerink partners Mentioned together
Leerink partners provides financial research reports and price targets regarding Illumina.
-
Donald Trump Shared context
Illumina's business model is exposed to the potential policy impacts of Trump-era tariffs and trade policies.
-
Bio-Rad Laboratories Operational
The companies collaborate on advanced life science technologies.
-
MarketBeat Mentioned together
MarketBeat aggregates and provides analyst ratings and price targets for Illumina.
-
Ark Invest Transactional
Ark Invest reduced its holdings in Illumina during a portfolio review.
-
TD Cowen Mentioned together
TD Cowen's analyst ratings and price targets influence market sentiment and stock price of Illumina.
-
Citigroup Transactional
Citigroup formally assessed Illumina by issuing a rating report.
-
Daiwa Securities Group Mentioned together
Daiwa Securities Group provided a stock rating upgrade and price target for Illumina.
-
Bloom Energy Mentioned together
Both Illumina and Bloom Energy are included as components of the S&P 500 index.
-
Investor's Business Daily Mentioned together
Investor's Business Daily published an analysis suggesting Illumina stock was overvalued.
-
Lilly Research Laboratories Shared context
The company leverages the research institution's expertise, and the institution benefits from industry context, establishing a shared strategic focus.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada has initiated and published financial coverage and ratings on Illumina stock, influencing market sentiment.
-
Keith Meister Transactional
Keith Meister, a director, sold a significant portion of his holdings in Illumina.
-
San Diego Shared context
Illumina operates out of its headquarters located in San Diego, California.
-
Barclays Mentioned together
Barclays analysts provide financial coverage and price targets for Illumina.
-
Chicago Shared context
The provided evidence describes Illumina's activities at ASCO but does not mention Chicago.
History
Events by the month they beganSeptember 2026
6 events- Analysis suggests that both Moderna and Illumina stocks are currently overvalued.
- VOO index undergoes changes including adding Illumina and Bloom Energy, while Builders FirstSource is removed. Separately, Fisher Investments promotes VOO strategies.
- Illumina achieved S&P 500 inclusion via index rebalancing, with the company headquartered in San Diego, CA.
- Illumina is accelerating the adoption of its technologies in clinical markets across Canada.
- Several companies, including Everpure and Bloom Energy Corporation, are scheduled to be added to the S&P 500 index, replacing existing members.
- Illumina and MindWalk Holdings Corp. have partnered, with both companies operating in the field of AI-enabled drug discovery.
August 2026
5 events- Meiji Yasuda Life Insurance Co increased its stake in Illumina shares and sold stock under a trading plan.
- TD Cowen raised its price objective on Illumina stock on August 26, 2026.
- MedLife and Illumina developed a full workflow in Romania using the NovaSeq X Plus platform.
- Illumina is offering its services in the US, UK, and Singapore, and providing analyst ratings.
- Illumina reported its financial results, showing a year-on-year revenue growth of 9.4% on August 4, 2026.
July 2026
6 events- Illumina and Bio-Rad Laboratories collaborate on advanced life science technologies.
- Citigroup issued a rating report on Illumina, while MarketBeat aggregated the stock rating data.
- Illumina reported that its Q2 revenue and EPS surpassed market expectations on July 30, 2026.
- Morgan Stanley grew its holdings in Illumina, and PNC Financial Services Group increased its holdings in Illumina shares on July 29, 2026.
- Fifth Third Bancorp increased its stake in Illumina stock on July 18, 2026.
- Illumina faces challenges from China's entity list and potential upside from Trump-era tariffs.
Show 1 earlier month
June 2026
41 events- Several companies, including Guardant Health and Myriad Genetics, are competing in the liquid biopsy market.
- Canaccord raised its price target for Illumina shares, noting that revenue growth driven by clinical customers and NovaSeq X adoption is key to expansion goals.
- NIH grant uncertainty is causing delays in academic projects involving various research entities.
- Barclays raised its price target on Illumina, which appointed an Eli Lilly executive to its board, while Roche launched a cheaper gene sequencing machine.
- Daiwa Securities Group upgraded its stock rating and price target for Illumina on June 29, 2026, while Royal Bank of Canada began coverage with an outperform rating.
- The acquisition of SomaLogic by Illumina is expanding Illumina's capabilities into proteomics and precision medicine.
- Illumina and Eli Lilly are strategically aligning through corporate appointments, including appointing an executive from Eli Lilly to another company's board.
- Illumina SVP sold 700 shares of the company.
- Royal Bank of Canada initiated coverage on Illumina stock.
- Morgan Stanley and Norges Bank boosted their holdings in Illumina during the 4th quarter.
- Illumina faces regulatory uncertainties in China.
- Illumina faces restricted instrument exports to China, prompting regulatory changes and analyst scrutiny from Bank of America.
- Illumina, AbbVie, Abbott Laboratories, Qiagen, and Eli Lilly are major players in the US personalized medicine market and are investing in related R&D.
- Emerging competition from Roche is a near-term concern for Illumina.
- Government support is fueling biotech innovation involving Illumina and Roche.
- Market growth in personalized medicine is being driven by demand, involving major players like Roche and Illumina.
- RingCentral, Hershey, and Illumina were analyzed for cash-producing stock risks on August 22, 2025.
- Illumina acquired SomaLogic for cash and royalties.
- Standard BioTools acquired SomaLogic, retaining reagent rights for Illumina, following a strategic sale of SomaLogic to Illumina.
- Illumina appointed Jacob Thaysen as CEO and Director.
- Illumina announced an agreement to acquire SomaLogic on September 3, 2025, utilizing SomaLogic's technology for new assays.
- Grail was formed following a spin-off from Illumina, and Morgan Stanley reiterated its 'Equal Weight' stance on the companies.
- Illumina was ranked second overall in the United States as of July 10, 2025.
- Illumina announced its results from San Diego.
- Illumina and Agenus were noted to operate within the same industry.
- Illumina and Qiagen are noted as top players in the tumor profiling market experiencing growth in Europe.
- Illumina and Harmony Biosciences Holdings, Inc. were classified as stocks in the Medical-Biomedical and Genetics sector on July 15, 2025.
- Sea expanded its services across Southeast Asia, with profitability analyses involving Sprinklr and Illumina.
- Illumina and DaVita HealthCare reported positive ESP figures on July 22, 2025.
- Cathie Wood invested in Illumina's disruptive life sciences.
- Illumina sold genomic-sequencing systems with software vulnerabilities, leading to an FDA warning.
- Baron Funds highlighted Illumina in its investor letter on August 5, 2025.
- Illumina reported that Europe contributed 29.3% of its total revenue in August 2025.
- Illumina, Pacific Biosciences, Microsoft, and Monster Beverage were mentioned as thematic investing winners in the life sciences tools and services segment.
- Illumina, Twist Bioscience, Ginkgo Bioworks, Amyris, Cargill, Moderna, and Vertex Pharmaceuticals are all key players in the AI in Synthetic Biology Market.
- GRAIL reported an impairment of assets related to its acquisition of Illumina.
- Illumina Inc. is based in San Diego, CA.
- Rate cut speculation on August 14, 2025, benefited growth sectors, including healthcare companies like Clover Health, Surgery Partners, Illumina, and Bruker.
- Illumina is establishing its regional head in Singapore.
- Illumina and Thermo Fisher Scientific are key players in the DNA forensics market.
- MicroGenDX incorporated Illumina's MiSeq platform to deliver leading-edge NGS testing, quickly identifying C. acnes.